Co-Diagnostics (CODX) Misses Q3 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Co-Diagnostics (CODX) Misses Q3 EPS by 10c

Co-Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

November 10, 2022 4:13 PM EST

Nearing commencement of clinical evaluations for the Co-Dx PCR Home platformCOVID-19 test volumes continue to impact third quarter results

SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2022.

Third Quarter 2022 Financial Results:

Revenue of $5.1 million, down from $30.1 million during the prior year period, but an... More